MCK

McKesson (MCK) closed at $1,015.50, down 1.42% on the day but up 15.58% over the past month. The prescription drug distributor is expected to report Q4 EPS of $10.69 (up 8.42% YoY) and revenue of $110.11 billion (up 6.75% YoY).

Full-year consensus estimates project $44.71 EPS and $429.01 billion revenue, representing 14.32% and 6.34% growth respectively. MCK trades at a Forward P/E of 23.04, above its industry average of 17.52, and holds a Zacks Rank #3 (Hold) rating.

McKesson (MCK) has outperformed the broader market with a +15.6% return over the past month, compared to the S&P 500's +0.7%. The company shows solid fundamentals with expected earnings growth of +14.3% for the current fiscal year and +11.8% for the next year.

However, with a Zacks Rank #3 (Hold) rating and minimal recent changes to earnings estimates (+0.1-0.3%), the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers (Grade B) and has consistently beaten consensus estimates.

McKesson (MCK) closed at $1,030.12, up 1.95%, outperforming the S&P 500's 0.28% gain. The prescription drug distributor has gained 13.98% over the past month.

Analysts project Q4 2026 earnings of $10.69 per share (8.42% YoY growth) and full-year earnings of $44.71 per share (14.32% YoY growth). MCK trades at a Forward P/E of 22.6, above its industry average of 17.17, and holds a Zacks Rank #3 (Hold) rating.

McKesson (MCK) closed at $976.57, up 1.53% and outperforming the S&P 500's 1.11% decline. The prescription drug distributor has gained 6.93% over the past month.

Analysts expect November 2026 earnings of $10.72 per share (8.72% YoY growth) and full-year earnings of $44.73 per share (14.37% growth). McKesson holds a Zacks Rank #2 (Buy) rating with a Forward P/E of 21.5, trading at a premium to its industry average of 17.49.

McKesson (MCK), a leading North American pharmaceutical distributor, receives a #3 (Hold) rating from Zacks with a VGM Score of A. The stock shows strong momentum with a B score and 5.6% gains over four weeks. Analysts have raised fiscal 2027 earnings estimates by $0.18 to $44.73 per share, with GLP-1 medications driving growth at nearly $41 billion in FY25 revenues.

A $1,000 investment in McKesson (MCK) made in October 2016 would be worth $5,610 as of October 9, 2026, representing a 461% gain. This significantly outperforms the S&P 500's 260.55% return over the same period.

McKesson's growth is driven by its pharmaceutical distribution business, specialty pharmaceuticals, oncology services, and GLP-1 medications, with FY26 revenues reaching $403.4 billion. The company is streamlining its portfolio and expanding its oncology network, though it faces headwinds from drug-pricing regulations and customer concentration risks.

McKesson Corporation (MCK) is featured as a #2 (Buy) stock with a VGM Score of A and Growth Style Score of A, forecasting 14.4% year-over-year earnings growth for fiscal 2025. The company, a leading pharmaceutical distributor in North America, benefits from strong growth in specialty pharmaceuticals, oncology services, and GLP-1 medications, which generated nearly $41 billion in FY25 revenues.

McKesson (MCK) closed at $910.33, down 1.23% in recent trading. The prescription drug distributor is expected to report earnings on November 4, 2026, with projected EPS of $10.8 (up 9.53% YoY) and revenue of $110.14 billion (up 6.78% YoY). The company holds a Zacks Rank #2 (Buy) rating with a Forward P/E of 20.6, trading at a premium to its industry average of 17.22.

McKesson (MCK) is highlighted as a top growth stock pick due to its strong earnings growth of 14.4% (above industry average of 7.7%), efficient asset utilization with an S/TA ratio of 4.85 versus industry average of 0.77, and positive earnings estimate revisions. The company earned a Growth Score of A and Zacks Rank #2 (Buy), positioning it well for outperformance among growth investors.

McKesson (MCK) has outperformed the S&P 500 over the past month with a +3.7% return. The company is expected to report 14.4% earnings growth for the current fiscal year with a Zacks Rank #2 (Buy) rating. Revenue is projected to grow 6.3% for the current fiscal year, and the stock is trading at a discount to peers with a B valuation grade.

Option Care Health agreed to be acquired by McKesson and private equity firm Clayton, Dubilier & Rice for $32.05 per share, valuing the company at approximately $5.8 billion. The deal represents a 37% premium to Monday's closing price and is expected to close in the first half of 2027. CD&R will hold 51% of the company while McKesson retains 49%, with a framework allowing McKesson to acquire CD&R's stake in the future.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

Several major companies reported quarterly earnings with mixed results. Accenture surged 15.8% after beating earnings estimates, while McKesson gained 5.3% on maintained guidance. Conversely, Acuity fell 3.4% and Progress Software dropped 8.5% after missing revenue expectations.

McKesson closed down 1.27%, underperforming the S&P 500's 0.25% loss. The stock has declined 4.63% over the past month, lagging the Medical sector.

The company is expected to report earnings on November 4, 2026, with projected EPS growth of 8.72% and revenue growth of 6.78% year-over-year. McKesson holds a Zacks Rank of #3 (Hold) with a Forward P/E of 19.37, trading at a premium to its industry average.

McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 following strong Q1 results with 20% EPS growth. The company is benefiting from robust growth in oncology services, specialty distribution, and GLP-1 therapies, which generated $15 billion in Q1 revenues. However, headwinds include branded drug price declines, generic conversion pressure, and regulatory uncertainty around 340B reform and IRA Part D changes.

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x).

Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

Europe's EHR market is expected to grow from US$8.05 billion in 2024 to US$15.37 billion by 2031, driven by AI adoption, cloud-based solutions, and government digital health initiatives. Cloud-based systems lead the market, with acute EHR and clinical records as primary segments.

Germany is the largest market contributor, supported by national digital strategy and mandatory e-prescriptions. Leading vendors are investing in product innovation, partnerships, and M&A to strengthen market presence.

The U.S. economy showed mixed signals with rising inflation (3.7% headline, 2.6% core) and geopolitical tensions pressuring markets. The Nasdaq fell 4.1% while the Dow gained 0.29%, reflecting investor preference for blue-chip stocks over tech. Despite market uncertainty, Zacks' research-driven rating systems demonstrated strong performance, with Valero Energy gaining 29.7% post-upgrade, Palantir surging 40.5% over 12 weeks, and the Zacks Rank #1 portfolio outperforming the S&P 500 by 3.9 percentage points year-to-date.

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.